Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
There is a growing consensus that drug discovery thrives in an open environment. Here, we describe how the malaria community has embraced four levels of open data — open science, open innovation, open access and open source — to catalyse the development of new medicines, and consider principles that could enable open data approaches to be applied to other disease areas.
A wave of companies are developing personalized vaccines, built from tumour-specific neo-antigens, providing a timely boost for a failure-ridden area of cancer immunotherapy.
Michael Rosenblatt, newly appointed Chief Medical Officer of Flagship Ventures and former Chief Medical Officer at Merck & Co., discusses his move from industry to venture capital.
Recent investments in nascent public biopharmaceutical companies indicate that companies focused on small-molecule approaches attracted more funding than might have been expected based on rates of return on investment compared with biologic approaches.
Over the past 25 years, biophysical technologies such as X-ray crystallography and nuclear magnetic resonance spectroscopy have become key components of drug discovery platforms in many pharmaceutical companies and academic laboratories. This article provides a framework to understand this evolution by describing the key biophysical methods, the information they can provide and the ways they can be applied at different stages of the drug discovery process.
The progression of prostate cancer to castration-resistant prostate cancer (CRPC) poses considerable therapeutic challenges. Johann de Bono and colleagues review the identification of possible drug targets in CRPC, the evolving CRPC therapeutic landscape and what the future of the treatment of the disease may hold.
Myokines are emerging as potential mediators of some of the beneficial effects of exercise on the body. Here, Whitham and Febbraio discuss the challenges facing the discovery and validation of myokines and highlight selected myokines with the potential to be therapeutically exploited in cancer and metabolic disease.
